<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337568</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0204</org_study_id>
    <nct_id>NCT03337568</nct_id>
  </id_info>
  <brief_title>Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission</brief_title>
  <acronym>AML_AlloHCT</acronym>
  <official_title>Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Research Institute of Bioscience and Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of various clinical variables including
      HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell
      transplantation (HCT) using uniform conditioning regimen including busulfan, fludarabine, and
      antithymocyte globulin (ATG) in patients with acute myeloid leukemia (AML) in the first
      complete remission (CR). The donors for allogeneic HCT include HLA-matched siblings, matched
      unrelated donors, and haploidentical family donors.

      Therefore, the endpoints of the study are engraftment, secondary graft failure, acute and
      chronic graft-versus-host disease (GVHD), immune recovery, infections, leukemia recurrence,
      non-relapse mortality, and relapse-free (RFS) and overall survival (OS) of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>leukemia recurrence</measure>
    <time_frame>from HCT (day of donor cell infusion) to leukemia recurrence at 2 years after HCT</time_frame>
    <description>reappearance of blast &gt;5% in bone marrow; reappearance of leukemia blast in extramedullary sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>engraftment</measure>
    <time_frame>from HCT to neutrophil count over &gt;500/uL at 30 days after HCT</time_frame>
    <description>recovery of absolute neutrophil count over &gt;500/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD, acute and chronic</measure>
    <time_frame>from HCT to the occurrence of GVHD at 2 years after HCT</time_frame>
    <description>occurrence of acute or chronic GVHD after HCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>from HCT to the occurrence of death without leukemia recurrence at 2 years after HCT</time_frame>
    <description>occurrence of death without leukemia recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>from HCT to last the follow-up, leukemia recurrence, or death at 2 years after HCT</time_frame>
    <description>survival without leukemia recurrence/death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from HCT to the last follow-up or death at 2 years after HCT</time_frame>
    <description>survival regardless of leukemia recurrence</description>
  </secondary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic cell transplantation</intervention_name>
    <description>perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood mononuclear cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a single center, observational study in a patient population with non-promyelocytic
        AML who have achieved complete remission after induction chemotherapy. The patients will be
        enrolled consecutively.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-promyelocytic AML (intermediate-risk or high-risk diseases by NCCN
             guideline 2016) in the first CR

          -  Patients should be 16 years of age or more and 75 years of age or less

          -  The performance status of the patients should be 70 or over by Karnofsky performance
             scale

          -  Patients should have adequate hepatic function (bilirubin less than 2.0 mg/dl, AST
             less than three times the upper normal limit)

          -  Patients should have adequate renal function (creatinine less than 2.0 mg/dl)

          -  Patients should have adequate cardiac function (ejection fraction &gt; 40% on MUGA scan)

          -  Patients and stem cell donors must sign informed consent

          -  For hematopoietic cell donor, if a patient has an HLA-matched sibling (65 years or
             younger), that sibling will be a cell donor. If a patient does not have an HLA-matched
             sibling but an HLA-A, B, C, DRB1 7-8/8 matched unrelated donor, the unrelated donor
             will be a cell donor. If a patient has neither HLA-matched sibling nor unrelated
             donor, an HLA-haploidentical familial donor will be a cell donor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo-Hyung Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulsan, Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyoo-Hyung Lee, MD</last_name>
    <phone>82-2-3010-3213</phone>
    <email>khlee2@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seunghyun Baek, RN</last_name>
    <phone>82-2-3010-7289</phone>
    <email>bsh5932@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoo-Hyung Lee, MD</last_name>
      <phone>82-2-3010-3213</phone>
      <email>khlee2@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Inpyo Choi, PhD</last_name>
      <phone>82-42-860-4223</phone>
      <email>ipchoi@kribb.re.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28.</citation>
    <PMID>21715313</PMID>
  </reference>
  <results_reference>
    <citation>Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25.</citation>
    <PMID>28552421</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyoo-Hyung Lee</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>AML CR</keyword>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <keyword>busulfan</keyword>
  <keyword>fludarabine</keyword>
  <keyword>ATG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

